RSH

0.00%

3.0¢ respiri limited

Thanks for sharing, I did not receive this. Neither company has...

First 2 Last

Mike77

4,848 Posts.

903

08/02/24

11:19

Post #: 72300775

Originally posted by Itrade123: ↑
Assume all shareholder received this? If you are not one, good to have public.

7th February 2024
1
Only Respiri Limited offers unique, patent protected, FDA-cleared medical devices for integration into RPM programs. Building on the hero wheezo®, with the recent addition of EchoSolv™ and now CONNEQT.
2
Having recognised the significant revenue opportunities Respiri Limited can provide, Cardiex (ASX:CDX) has entered into an exclusive RPM commercial distribution agreement with Respiri Limited by integrating Cardiex’s, FDA-cleared CONNEQT Pulse cardiovascular biomarker device into Respiri's comprehensive solution for Remote Patient Monitoring programs, further differentiating the Respiri Remote Patient Monitoring device portfolio.

Cardiovascular RPM that monitors more than simple blood pressure. Key Highlights:
Integrating CARDIEX's CONNEQT Pulsevascular biomarker device into Respiri's RPM programs, creates a comprehensive RPM cardiovascular solution that goes beyond simple blood pressure and includes other cardiovascular physiological parameters.

The combination of these data sets will provide Respiri’s Care Specialist team with unique clinical insights that can help drive better patient outcomes.

More comprehensive monitoring and data will drive further reductions in healthcare costs- critical to the risk-share and other contract types Respiri has and will secure in future with Accountable Care Organisations (ACO), Independent Physician Associations (IPAs) and insurers/payors.

CONNEQT Pulse device will provide opportunity for additional revenues for Respiri through improved cost savings in risk-share contracts and by securing additional RPM clients interested in the unique additional data that CONNEQT can provide the Respiri Care Specialists and decisions that this will likely facilitate.
Expand
Thanks for sharing, I did not receive this.

Neither company has made any announcement but still good to see the offering widening.

At current SP, with cash in the bank and 6 contracts in negotiation this is looking like a good prospective buy ATM

RSH Price at posting: 2.6¢ Sentiment: Buy Disclosure: Held

3 Upvote

0 Great analysis

There are more pages in this discussion • 28 more messages in this thread...

First 2 Last

Add RSH (ASX) to my watchlist

(20min delay)
Last 3.0¢		Change 0.000(0.00%)		Mkt cap ! $31.79M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Buyers (Bids)

No.	Vol.	Price($)
3	444621	2.7¢

Sellers (Offers)

Price($)	Vol.	No.
2.9¢	212939	1

View Market Depth

No.	Vol.	Price($)
3	444621	0.027
1	300000	0.026
3	289495	0.025
1	50000	0.024
1	220000	0.022

Price($)	Vol.	No.
0.029	212939	1
0.030	608207	1
0.032	433802	2
0.033	130000	1
0.035	92678	1

Last trade - 10.35am 03/05/2024 (20 minute delay)

RSH (ASX) Chart

Day chart unavailable

Thanks for sharing, I did not receive this. Neither company has...

7th February 2024

Featured News

Provident Aurum's off-market bid sends Sihayo shares soaring

Lithium Universe ends the quarter charged up for Quebec Refinery roll-out

Macquarie profits fall 32% on 'market volatility' and low-achieving 'green investments'

BPH Energy renews NT Bonaparte Basin permit

Why Princeton Professor rates BlinkLab's autism & ADHD screening app

Buyers (Bids)

Sellers (Offers)

Featured News

	7th February 2024
1	Only Respiri Limited offers unique, patent protected, FDA-cleared medical devices for integration into RPM programs. Building on the hero wheezo®, with the recent addition of EchoSolv™ and now CONNEQT.
2	Having recognised the significant revenue opportunities Respiri Limited can provide, Cardiex (ASX:CDX) has entered into an exclusive RPM commercial distribution agreement with Respiri Limited by integrating Cardiex’s, FDA-cleared CONNEQT Pulse cardiovascular biomarker device into Respiri's comprehensive solution for Remote Patient Monitoring programs, further differentiating the Respiri Remote Patient Monitoring device portfolio. Cardiovascular RPM that monitors more than simple blood pressure. Key Highlights: Integrating CARDIEX's CONNEQT Pulsevascular biomarker device into Respiri's RPM programs, creates a comprehensive RPM cardiovascular solution that goes beyond simple blood pressure and includes other cardiovascular physiological parameters. The combination of these data sets will provide Respiri’s Care Specialist team with unique clinical insights that can help drive better patient outcomes. More comprehensive monitoring and data will drive further reductions in healthcare costs- critical to the risk-share and other contract types Respiri has and will secure in future with Accountable Care Organisations (ACO), Independent Physician Associations (IPAs) and insurers/payors. CONNEQT Pulse device will provide opportunity for additional revenues for Respiri through improved cost savings in risk-share contracts and by securing additional RPM clients interested in the unique additional data that CONNEQT can provide the Respiri Care Specialists and decisions that this will likely facilitate.

Thanks for sharing, I did not receive this. Neither company has...

Featured News

Top Stories

Provident Aurum's off-market bid sends Sihayo shares soaring

Lithium Universe ends the quarter charged up for Quebec Refinery roll-out

Macquarie profits fall 32% on 'market volatility' and low-achieving 'green investments'

BPH Energy renews NT Bonaparte Basin permit

Why Princeton Professor rates BlinkLab's autism & ADHD screening app

Buyers (Bids)

Sellers (Offers)

Featured News